HER2-Breast Cancer: Kay market research findings
- Emerging new therapies and procedures
- Rise in public awareness and patient assistance programs
Technavio has added a new market research report on the global HER2 negative breast cancer market, to its breast cancer portfolio. Technavio’s market research analysts estimate the HER2 negative breast cancer market to grow at a CAGR of around 16% between 2015 and 2019. The Americas dominate this market, followed by the EMEA and the APAC regions. In the Americas, the US is estimated to be the highest revenue contributor due to factors like high-unmet medical needs of patients and the expected launch of pipeline products in the next four years.
The new industry research report from Technavio discusses in detail the key drivers and trends responsible for growth, as well as the segments with the maximum growth potential.
“Entry of new drugs and therapies in the market is expected to boost treatment aspects of HER2-negative breast cancer. The demand for HER2-negative targeted therapies is high because of the increasing patient pool as well as the surging unmet medical needs to meet the requirements. BioMarin’s talazoparib, AbbVie’s ABT-888/veliparib, and AstraZeneca’s Lynparza/olaparib are the PARP inhibitors that are estimated to enter this market during the forecast period. Vendors are soon to introduce late-stage pipeline molecules like Eli Lilly’s abemaciclib/LY2835219 and Novartis’ BKM120/buparlisib,” says Imran Mushtaq, Lead Abalyst, Healthcare, Technavio Research.
Expensive cancer treatment procedures have led to increase in patient assistance programs. Various reimbursement plans such as public reimbursement programs are introduced to minimise the financial load of such expensive treatments. For instance, the Affordable Care Act adopted by the US government makes premium-priced drugs available at affordable rates. Several market vendors such as Novartis and Pfizer have specially designed financial assistance programs to make the drugs more affordable to patients, with the help of reimbursements or co-pay cards.
Various awareness and screening programs have gained momentum in the breast cancer treatment. Lack of early detection has increased the mortality risks associated with breast cancer. Awareness programs assist in prompt diagnosis of breast cancer in early stages. For instance, National Breast Cancer Foundation observe October as the Breast Cancer Awareness month each year. The American Breast Cancer Foundation offers financial aid to breast cancer patients for diagnosis and screening of the disease. Also, breastcancer.org provides updated information about the disease.
The key vendors in the global HER2-negative breast cancer are F. Hoffmann-La Roche, Novartis, and Pfizer. This market is highly competitive and contains numerous local and multinational players. The local vendors in this market supply chemotherapeutic drugs to treat this condition and, therefore, are rapidly gaining traction in this market.
A more detailed analysis is available in the Technavio report, Global HER2-Negative Breast Cancer 2015-2019.
We can customize reports by other regions and specific segments upon request.
Other Related Reports:
